Company Description
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer.
The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients.
CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020.
CG Oncology, Inc. was founded in 2010 and is based in Irvine, California.
| Country | United States |
| Founded | 2010 |
| IPO Date | Jan 25, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 61 |
| CEO | Arthur Kuan |
Contact Details
Address: 400 Spectrum Center Drive, Suite 2040 Irvine, California 92618 United States | |
| Phone | 949 409 3700 |
| Website | cgoncology.com |
Stock Details
| Ticker Symbol | CGON |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001991792 |
| ISIN Number | US1569441009 |
| Employer ID | 37-1611499 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Arthur Kuan | Chairman and Chief Executive Officer |
| Ambaw Bellete M.S. | President and Chief Operating Officer |
| Dr. Vijay Kasturi M.D. | Chief Medical Officer |
| Corleen M. Roche | Chief Financial Officer and Secretary |
| Amy Steele | Vice President of Finance, Accounting and Administration |
| Swapnil Bhargava Ph.D. | Chief Technical Officer |
| Joshua F. Patterson | General Counsel and Chief Compliance Officer |
| Sarah Connors | Vice President of Communications and Patient Advocacy |
| Bing Kung | Vice President of Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2025 | 8-K | Current Report |
| Dec 13, 2024 | 424B4 | Prospectus |
| Dec 12, 2024 | EFFECT | Notice of Effectiveness |
| Dec 11, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Dec 11, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 6, 2024 | 144 | Filing |
| Dec 5, 2024 | 8-K | Current Report |
| Nov 21, 2024 | UPLOAD | Filing |
| Nov 14, 2024 | DRS | [Cover] Draft Registration Statement |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |